To be considered a success, Abivax's oral drug Obifazomad must demonstrate placebo-adjusted long-term remission rates of 25-30% in upcoming data, matching the efficacy of top biologic treatments for ulcerative colitis. Its strong phase two results, showing a 48% rate, suggest this benchmark is achievable, positioning it as a potential "holy grail" oral therapy.
Iovance is viewed as a top idea because investors previously misunderstood its core opportunity. The negative sentiment ignored the growth outlook in second-line melanoma, improving margins, and the significant upside from a potential non-small cell lung cancer approval in 2027—a much larger market. This reassessment is driving the stock's recent momentum.
The market is overly focused on competitive threats to Legend Biotech, causing it to miss the company's fundamental strength. Its drug Carvicti achieved $1.9B in 2025 sales and is projected to grow 50% in 2026. With profitability expected this year and an unpriced pipeline, the stock appears poised for growth despite negative sentiment.
Turns' drug, Turn 701, shows a significant valuation disconnect. Despite demonstrating molecular responses three times better than Novartis's Symblix—a drug with a $4B+ peak sales forecast—Turns' market cap is only 1.2 times that peak sales figure. This superior efficacy in a tough-to-treat population suggests considerable remaining upside for the stock.